(Q51021353)

27 March 2018

title

FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. (English)

1 reference

27 March 2018

Lorete Maria da Silva Kotze

1 reference

object named as

Lorete Maria da Silva Kotze

1

1 reference

ORCID Public Data File 2021

Renato M. Nisihara

2

object named as

Renato Mitsunori Nisihara

1 reference

27 March 2018

Paulo Gustavo Kotze

5

object named as

Paulo Gustavo Kotze

1 reference

27 March 2018

author name string

Sandra Beatriz Marion

3

1 reference

27 March 2018

Murilo Franco Cavassani

4

1 reference

27 March 2018

publication date

1 January 2015

1 reference

27 March 2018

Arquivos de Gastroenterologia

published in

1 reference

27 March 2018

volume

52

1 reference

27 March 2018

issue

1

1 reference

27 March 2018

page(s)

50-54

1 reference

27 March 2018

Fecal markers: calprotectin and lactoferrin

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Role of faecal calprotectin as non-invasive marker of intestinal inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Assessment of the response of patients with Crohn's disease to biological therapy using new non-invasive markers: lactoferrin and calprotectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Biomarkers in diverticular diseases of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Laboratory markers in IBD: useful, magic, or unnecessary toys?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Faecal calprotectin concentrations in gastrointestinal diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Subclinical intestinal inflammation: an inherited abnormality in Crohn’s disease relatives?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

Fecal Calprotectin in Clinical Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000100011

10.1590/S0004-28032015000100011

21 January 2018

Identifiers

DOI

1 reference

27 March 2018

1 reference

27 March 2018